118th Congress · SENATE BILLBILL

S. 2454Pharmaceutical Supply Chain Security Act

A bill to require reports on and investments in pharmaceutical supply chain resiliency to reduce reliance on the People's Republic of China for finished pharmaceutical products and active pharmaceutical ingredients.

Health
Introduced Jul 20, 2023
Last action Jul 20, 2023
Pipeline · Bill → Law
Step 1
Introduced
Jul 20, 2023
Step 2
Referred
Jul 20, 2023
Foreign Relations
Step 3
Committee
Step 4
Senate
Step 5
House floor
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary

This bill directs certain agencies to report on and reduce the role of China in pharmaceutical supply chains. Specifically, the Food and Drug Administration must report on pharmaceutical products and ingredients for which China supplies more than 20% of the quantities available in the United States. In addition, the President must develop a strategy to address the role of China in the global pharmaceutical supply chain and related threats to national security. The United States International Development Finance Corporation must also support manufacturing projects that promote the security of pharmaceutical supply chains, reduce reliance on China, and foster cooperation with other countries.

Provisions · 2 sectionsIntroduced in Senate
Timeline · 2 actions
Jul 20, 2023
Introduced in Senate
Jul 20, 2023
Read twice and referred to the Committee on Foreign Relations.